Risklick launches flagship product following an investment by Debiopharm

Developing new therapies typically requires an average of ten years and costs up to two billion dollars for companies. The most time-consuming and costly aspect of this process is the clinical trials, which are mandatory for validating new treatments before commercialization. These trials are complex, often resulting in significant delays or failures that impact both the cost and availability of new treatments for patients.

Clinical trials rely on complex protocols developed by experts, which describe all practical modalities of conducting the trial. Developing a protocol demands an average of 15 months of intensive work, where errors can have disastrous consequences.

To address these challenges, Risklick has developed Protocol AI, which reduces development time and costs by up to 35%. Protocol AI optimizes protocol development by leveraging data-driven insights from a comprehensive dataset of global historical trial data. This method not only reduces both time and costs but also ensures consistency across trials.

By using Protocol AI, experts can reduce protocol development time, make evidence-based decisions, and minimize the likelihood of amendments. The process involves three steps: exploring historical trial data, selecting key parameters based on evidence, and efficiently developing tailored protocols with generative AI. This approach accelerates innovation and the delivery of new treatments to patients, paving the way for medical advancement.

Risklick has partnered with leading biotechnology and medical device companies, including Debiopharm and ISS AG. Debiopharm has invested in the Bern-based startup via its Innovation Fund. “This investment in Risklick is part of our strategy to equip our collaborators in the R&D, Clinical Operations, Regulatory Affairs departments with a collaborative tool designed to enhance their workflows, facilitate trial design and support regulatory compliance. We are committed to addressing internal pain points by introducing or supporting through innovative solutions”, explains Cedric Odje, Investment Associate at Debiopharm Innovation Fund.

Dr. Poorya Amini CEO and co-founder of Risklick, adds: “We are on a mission to revolutionize clinical trial protocol development with our disruptive approach and technology.  Our vision is to become the standard in clinical trial protocol development, making trials faster, cheaper and safer for the benefit of all.”

(Press release / SK)